Only one drug, Roche's Xenical, is currently approved for long-term use in treating obesity, and it is unpopular because of embarrassing digestive side effects.
In contrast, although digestive side effects of sunitinib and vandetanib are quite similar to those of sorafenib, only a minority of PET studies performed in patients treated by the two former showed grade 4 uptake.
Transient visual and digestive side effects were observed more frequently in the TXA group than in the control group (17 vs 4 P = 0.028).
Furthermore, in the studies included in the meta-analysis by Moruisi et al. [ 41] only minor digestive side effects were reported that were not confirmed in other studies [ 53].
If any of your medications list gas, bloating, nausea, or other digestive stress as side effects, it may be a good idea to take a break, or ask your doctor about switching to an alternative option.
In 2,817 patients of all ages, but with a predominance of patients aged between 60 and 80 years old who had different neurological conditions, only 5.01% of the patients experienced side effects, mostly digestive intolerance.
On the plus side, because it works primarily in the digestive tract, it potentially has fewer side effects.
Xenical works by ensuring that fat intake passes through the digestive tract unabsorbed — though some unpleasant side effects make it unsuitable for recreational overeaters.
Research has shown that less than this amount is safe to consume daily over time, but if too much zinc is taken long-term, side effects may include digestive upset, a metallic taste in the mouth, dizziness, headaches, fatigue, increased sweating, loss of muscle coordination, alcohol intolerance, and hallucinations.
However, the treatment causes strong side effects such as digestive symptoms (vomiting and diarrhea) and bone marrow suppression.
However, the use of antibiotic therapy is often accompanied by undesirable side effects involving the digestive system and genitourinary tract as well as the development of bacterial resistance [ 9, 10].
